<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Miescher S</dc:creator>
  <dc:creator>Spycher MO</dc:creator>
  <dc:creator>Amstutz H</dc:creator>
  <dc:creator>De Haas M</dc:creator>
  <dc:creator>Kleijer M</dc:creator>
  <dc:creator>Kalus UJ</dc:creator>
  <dc:creator>Radtke H</dc:creator>
  <dc:creator>Hubsch A</dc:creator>
  <dc:creator>Andresen I</dc:creator>
  <dc:creator>Martin RM</dc:creator>
  <dc:creator>Bichler J</dc:creator>
  <dc:date>2004</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">A single recombinant immunoglobulin G1 (IgG1) anti-RhD antibody (MonoRho) was compared with a currently used polyclonal anti-RhD product (Rhophylac) in a phase 1 study for safety, efficacy of Rhesus D (RhD)-positive red blood cell (RBC) clearance, and prevention of RhD immunization in RhD-negative men challenged with 15 mL RhD-positive RBCs. Both the polyclonal product and recombinant anti-RhD effectively cleared RhD-positive RBCs after intravenous and intramuscular injection. The recombinant anti-RhD demonstrated a slower clearance rate compared with the polyclonal anti-RhD. There was no dose response, and there was considerable variation among subjects who received the same dose of recombinant anti-RhD. Interestingly, RhD-positive RBC clearance rates were strongly associated with Fcgamma receptor IIA (FcgammaRIIA) and FcgammaIIIA but not with FcgammaIIIB polymorphisms. Subjects homozygous for FcgammaRIIA-131H or FcgammaRIIIA-158V allotypes showed a faster clearance rate compared with both the heterozygote and the corresponding alternative homozygote allotypes. A similar but less marked trend was seen for the polyclonal anti-RhD. Despite the variation in clearance rates there was no evidence of anti-RhD alloantibodies in any of the subjects at +6 months after the RBC challenge.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://sonar.ch/global/documents/192944</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1182/blood-2003-11-3929</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/14976055</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:source>Blood. - 2004</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Adolescent</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Adult</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Antibodies, Monoclonal</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Antigens, CD</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Erythrocytes</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Follow-Up Studies</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">Immunization</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">Immunoglobulin G</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">Male</dc:subject>
  <dc:subject xmlns:ns11="xml" ns11:lang="en">Middle Aged</dc:subject>
  <dc:subject xmlns:ns12="xml" ns12:lang="en">Polymorphism, Genetic</dc:subject>
  <dc:subject xmlns:ns13="xml" ns13:lang="en">Protein Binding</dc:subject>
  <dc:subject xmlns:ns14="xml" ns14:lang="en">Receptors, IgG</dc:subject>
  <dc:subject xmlns:ns15="xml" ns15:lang="en">Recombinant Proteins</dc:subject>
  <dc:subject xmlns:ns16="xml" ns16:lang="en">Rh-Hr Blood-Group System</dc:subject>
  <dc:title xmlns:ns17="xml" ns17:lang="en">A single recombinant anti-RhD IgG prevents RhD immunization: association of RhD-positive red blood cell clearance rate with polymorphisms in the FcgammaRIIA and FcgammaIIIA genes.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
